Background Infection is a key component of bronchiectasis pathophysiology.
Characterisation of the microbiome offers a higher degree of sensitivity and resolution than …

Background Bronchiectasis is accompanied by chronic bronchial infection that may drive
disease progression. However, the evidence base for antibiotic therapy is limited. DNA …

Bronchiectasis is increasing in prevalence worldwide, yet current treatments available are
limited to those alleviating symptoms and reducing exacerbations. The pathogenesis of the …

Rationale: Although inflammation and infection are key disease drivers in bronchiectasis,
few studies have integrated host inflammatory and microbiome data to guide precision …

Rationale: Characterization of bacterial populations in infectious respiratory diseases will
provide improved understanding of the relationship between the lung microbiota, disease …

Bronchiectasis is a disease associated with chronic progressive and irreversible dilatation of
the bronchi and is characterised by chronic infection and associated inflammation. The …

Rationale: Although airway microbiota composition correlates with clinical measures in non–
cystic fibrosis bronchiectasis, these data are unlikely to provide useful prognostic information …

Rationale Despite the potentially important roles for infection in adult non-cystic fibrosis (CF)
bronchiectasis disease progression, the bacterial species present in the lower airways of …

Rationale: Bronchiectasis and chronic obstructive pulmonary disease (COPD) are two
disease entities with overlapped clinical features, and codiagnosis frequently occurs (termed …

Bronchiectasis is a heterogeneous disease. This study aimed at identifying discrete groups
of patients with different clinical and biological characteristics and long-term outcomes. This …